Causes of Visual Loss in Retinal Disease
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a study of visual outcomes in retinal disease that seeks to identify the causes of visual loss. This data will be used to predict which patients are at risk of losing vision and how they can be better treated.
| Condition | Intervention |
|---|---|
|
Uveitis Scleritis |
Drug: Immunosuppressive Agents |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Retrospective |
| Official Title: | Observational Study of Visual Outcomes in Retinal Disease |
- Visual acuity at 5 years [ Time Frame: 5 years ] [ Designated as safety issue: No ]Best-corrected visual acuity at 5 years
- Visual acuity at 10 years [ Time Frame: 10 years ] [ Designated as safety issue: No ]Best corrected visual acuity at 10 years
- Source of referral [ Time Frame: Baseline ] [ Designated as safety issue: No ]Categorised as A&E/GP referral/Optician referral/Tertiary referral
- Laterality [ Time Frame: Baseline ] [ Designated as safety issue: No ]
Categorised as:
Right eye/Left eye/Bilateral
- Anatomical diagnosis [ Time Frame: Baseline ] [ Designated as safety issue: No ]
Cateogorised as:
Acute anterior uveitis / Chronic anterior uveitis / Fuchs heterochromic cyclitis / Intermediate uveitis / Pars planitis / Posterior Uveitis / Panuveitis / Episcleritis / Scleritis
- Aetiological diagnosis [ Time Frame: Baseline ] [ Designated as safety issue: No ]
Diagnosed as:
Viral / Bacterial / Fungal / Parasitic / Inflammatory / Malignant
- Associated systemic disease [ Time Frame: Baseline ] [ Designated as safety issue: No ]Any associated systemic disease, e.g. HLA-B27 associated disease, Behcet's disease, multiple sclerosis, Vogt-Koyanagi-Harada syndrome, rheumatoid arthritis, collagen vascular disease, tuberculosis, granulomatosis with polyangiitis
- Complications of disease and causes of visual loss at 5 years [ Time Frame: 5 years ] [ Designated as safety issue: No ]
Categorised into:
Corneal clarity problems / cataract / vitreous debris / retinal detachment / cystoid macular edema / retinal pigment epithelium atrophy / macular scarring / epiretinal membrane / macular hole / steroid response / glaucoma / other optic neuropathy / hypotony & phthisis / other
- Complications of disease and causes of visual loss at 10 years [ Time Frame: 10 years ] [ Designated as safety issue: No ]
Categorised into:
Corneal clarity problems / cataract / vitreous debris / retinal detachment / cystoid macular edema / retinal pigment epithelium atrophy / macular scarring / epiretinal membrane / macular hole / steroid response / glaucoma / other optic neuropathy / hypotony & phthisis / other
- Complications of disease and causes of visual loss [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]
Categorised into:
Corneal clarity problems / cataract / vitreous debris / retinal detachment / cystoid macular edema / retinal pigment epithelium atrophy / macular scarring / epiretinal membrane / macular hole / steroid response / glaucoma / other optic neuropathy / hypotony & phthisis / other
- Treatment measures employed [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]
Categorised into:
Topical treatment / periocular steroid / intraocular steroid / intraocular other agent / Glaucoma treatment / systemic immunosuppressive agents
- Complications of disease and treatment [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]
Categorised into:
- Local complications: Raised intraocular pressure / cataract / endophthalmitis / other
- Systemic complications: Diabetes / hypertension / cholesterol / liver function / bone density loss / other
- Surgical procedures [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]List and dates of any intraocular surgery performed during the study
- Burden of disease - appointments [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]Number of outpatient appointments over the course of the study
- Burden of disease - outpatient procedures [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]Number of outpatient procedures over the course of the study
- Burden of disease - inpatient procedures [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]Number of inpatient procedures over the course of the study
- Blind registration [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]Year of any registration as partially sighted or blind
| Estimated Enrollment: | 2000 |
| Study Start Date: | May 2012 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Patients with ocular inflammation
Patients with ocular inflammation
|
Drug: Immunosuppressive Agents
Treatment with systemic corticosteroids and/or immunosuppressive agents Treatment with local corticosteroids and other drugs
Other Names:
|
Detailed Description:
This is a study of visual outcomes in retinal disease. It is an observational study of patients who have been seen in the retinal clinic, and involves a retrospective casenotes analysis to identify patients who have suffered visual loss and the reason for that visual loss. These data will be analysed to enable the identification of factors that predict visual loss in patients who present earlier in the course of their disease.
Eligibility| Ages Eligible for Study: | 16 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients with ocular inflammation
Inclusion Criteria:
- patients with a diagnosis of ocular inflammation
- patients with at least 6 months of follow-up
Exclusion Criteria:
- patients without a diagnosis of ocular inflammation
- patients with less than 6 months of follow-up
Contacts and Locations| United Kingdom | |
| Royal Surrey County Hospital | |
| Guildford, UK, United Kingdom, GU2 7XX | |
| Moorfields Eye Hospital | |
| London, United Kingdom, EC1V 2PD | |
| Principal Investigator: | Simon RJ Taylor, PhD FRCOphth | Royal Surrey County Hospital |
More Information
No publications provided
| Responsible Party: | Simon Taylor, Senior Lecturer & Consultant Ophthalmic Surgeon, Royal Surrey County Hospital |
| ClinicalTrials.gov Identifier: | NCT01613963 History of Changes |
| Other Study ID Numbers: | 12DEV0010 |
| Study First Received: | May 29, 2012 |
| Last Updated: | June 5, 2012 |
| Health Authority: | United Kingdom: National Health Service |
Keywords provided by Royal Surrey County Hospital:
|
Uveitis Scleritis |
Additional relevant MeSH terms:
|
Retinal Diseases Scleritis Uveitis Chorioretinitis Eye Diseases Scleral Diseases Uveal Diseases Retinitis Choroiditis Choroid Diseases Uveitis, Posterior Panuveitis Azathioprine Methotrexate Cyclosporine |
Immunosuppressive Agents Mycophenolate mofetil Prednisolone Mycophenolic Acid Antimetabolites Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Antimetabolites, Antineoplastic Antineoplastic Agents Therapeutic Uses Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antifungal Agents Anti-Infective Agents |
ClinicalTrials.gov processed this record on May 23, 2013